Lotte Bjerre Knudsen

Lotte Bjerre Knudsen, Novo Nordisk’s Chief Scientific Advisor, shares her remarkable journey in discovering semaglutide, the molecule behind Ozempic. She reveals the initial skepticism faced in the 90s and her steadfast belief in its potential for weight loss, which was a goal from the start. Lotte discusses the complex mechanisms of GLP-1 agents, how they impact appetite and weight management, and the innovative pharmaceutical testing processes enhancing drug effectiveness. Her insights shed light on the collaborative spirit necessary in biomedical science.

Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, is a trailblazer in GLP-1 drug development for obesity and Alzheimer's. She shares her journey from enzyme research to impactful innovations. The discussion dives into the surprising link between GLP-1 drugs and weight loss in Type 2 diabetes patients. Lotte also highlights the future of these treatments in tackling neurodegenerative diseases. Additionally, she addresses the challenges faced by women in science and the need for collaboration and equality in research.